Upper GI 2017

First page Table of contents Previous page 1036 Next page Last page

Survival gain by Trastuzumab in HER2-positive stage IV gastric cancer: the ToGA trial

Bang et al. Lancet 2010

• Therapeutically relevant HER2 positivity: ~ 16% • Trastuzumab in HER2-positive stage IV gastric cancer: Survival 16.0 vs. 11.8 months (HR=0.65; 95% CI 0.51-0.83)

Made with